Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I hope Dale gets a favorable decision from the Appeals Court on Tuesday, and that I don't have to spend time on what looks like a complicated set of circumstances. We'll know soon enough.
But when you take the design of our share structure, involving ~ 6-8 entities controlled by Dale, and the Admin Proceeding filed against Murchinson, it's easy for the SEC to force Dale to prove his innocence, which is NOT the way the system is designed, except for the IRS.
"1. These proceedings concern Respondents causing the executing brokers of
a hedge fund (the “Hedge Fund”) to violate the order-marking and locate requirements of
Regulation SHO of the Exchange Act, and Respondents Murchinson and Bistricer (the
“Murchinson Respondents”) causing the Hedge Fund to act as a dealer without
registering with the Commission, or being exempt from registration, in violation of
Section 15(a)(1) of the Exchange Act.2
2. From January 2016 through October 2017 (the “relevant period”),
Respondents caused the Hedge Fund to place “long” sale orders with its brokers. At the
time hundreds of these orders were entered, the Hedge Fund was not “deemed to own”
the stock being sold and did not have a net long position in the stock for the purposes of
Regulation SHO. Respondents should have identified these orders as “short” sales.
Because this order-marking information was erroneous, Respondents caused the Hedge
Fund’s executing brokers to mismark such sale orders as “long” in violation of Rule
200(g) of Regulation SHO."
https://www.sec.gov/files/litigation/admin/2021/34-92684.pdf
This was further complicated by the Kalobios name change to Humanigen at this time.
"KaloBios Pharmaceuticals Inc. will change its name to Humanigen Inc., effective Aug 7.
The new name reflects the company's focus on neglected and rare disease, said Cameron Durrant, managing director, chairman and CEO of KaloBios."
https://www.globenewswire.com/news-release/2017/07/27/1063782/0/en/KaloBios-To-Change-Company-Name-To-Humanigen-Inc.html
As far as Humanigen's previous CEO, the SEC (heck, the whole US government), had a problem with him.
"The Securities and Exchange Commission (“Commission”) deems it appropriate and in the
public interest that public administrative proceedings be, and hereby are, instituted pursuant to
Section 203(f) of the Investment Advisers Act of 1940 (“Advisers Act”) against Martin Shkreli
(“Shkreli” or “Respondent”)."
https://www.sec.gov/files/litigation/admin/2017/ia-4753.pdf
Even among senior Humanigen shareholders here, there are a number of them who swear up and down that the Form 4's prove that insiders were selling shares, while I think they were only transferring shares between nominee and beneficial owner accounts.
I'm assuming that the action Dale is Appealing is related to the above charges against Murchison. If that is not the case, I'll continue to look for an Admin Proceeding or Litigation Release naming Black Horse.
My nonchalant attitude is because, if these charges really do stem from the Murchinson case, it will be easy for Dale to prove that any funds disgorged from his entities should be returned.
I think this is an over-zealous prosecution by the SEC against all things Shkreli and Kalobios related, especially as our initial recall of our loaned shares would not have been possible if the SEC was controlling naked shorting of the company's stock. That's a lesson that they still haven't learned.
I really should continue to look for the charges relevant to this case. I'll do it if I have to, but the case may be Appealed before then, and I have a lot of confidence in Dale. Fire at will, Dale!
I have no doubt that you want me to be proven right. That's why I was happy to see that you continued to add to your position. Nothing I see gives me reason to stop being supportive of management.
I even think that if I was wrong about some of the things I said, then Dale would not have filed an Appeal. So I take the Appeal as a sign that I was right, even though I haven't seen either the charges or the Appeal.
Hold your fire. Hearing adjourned until the 23rd.
https://document.epiq11.com/document/getdocumentbycode?docId=4283561&projectCode=HUM&source=DM
Fire at will !
There is no reason to stop being supportive of Humanigen, as they continue to execute their business strategy, even while they integrate a stronger structural base.
I believe VERY STRONGLY in lenzilumab. Speaking just as a shareholder, I think lenz will have a shocking level of commercial success, maybe unparalleled in it's scope. That's very important to me. So I want to develop as much appreciation of this opportunity as I can. I want to have some expectations of what to look for.
If all I did was dwell on the PPS, or the delayed filings, I would be clueless about the potential I have for success with lenz. I'm glad that's not me. I guess I'd rather expect too much, than to settle for too little.
It's really not about me doing what management should be doing. I'm not qualified to do that. But to the extent that I can learn about this drug on my own, I think it's in my own best interest to do so.
I'm not Cameron nor Dale. We have a pathway to success.
Awww, and I didn't even mention that the judge denied the Settlement Agreement, to delist the shares, agreed to by the Bankruptcy Trustee and the SEC, after we objected to it. It's all a matter of record. But, you know that.
And don't forget that my case centered on the illegal trades that mainly went through Penson Financial for clearing. By the time the SEC filed Naked Shorting charges against Penson, they had wreaked so much damage to the American equity market, that the market was within three days of crashing. An Emergency Rule Change, to transfer accounts away from Penson, had to be approved by the SEC.
What little we are seeing from the SEC in Humanigen's case appears to be following the same abuse of discretionary authority they exhibited in the SpongeTech case. All I see is that the SEC has no regard, not for safeguarding investments to pay for life events, but neither does the FDA, NIAID, and the NIH have any regard for the millions of preventable deaths they are permitting by keeping the clinically-proven, peer-reviewed, more effective lenzilumab off the market.
He will never acknowledge that the Canadian stock regulators took disciplinary action on the exact issuances of shares I identified, and in which the US beneficiaries receiving shares from that same transaction block were never charged. Nor will he mention that Judge Denise Cote, who wrote the SEC v Cavanagh decision, again took action against several of the defendants in that case, after I notified her that those same defendants were involved in the SpongeTech case, and had been, even before her original case had been decided.
Since you asked, I think Durrant will merge one of his Taran entities into the hollowed-out Humanigen subsidiary, and that newly-formed entity will become the parent company of Humanigen.
How he may shuffle the deck, including his other Taran entity (the one without control of our product pipeline), and the remaining Humanigen subsidiaries, is anyone's guess. He may look at dedicating the other subsidiaries to specific medical fields, because I see wide open spaces to focus on beyond covid and oncology, as I recently noted in regards to MS and malaria, and then look to enter into further partnerships to advance those opportunities.
In addition, we have long-standing partnership interests in fields such as arthritis and asthma, which are mature markets, but they are large, and as it does, lenz will possibly revolutionize the treatment of those indications, giving us huge opportunity in these developed areas.
I am not only entirely comfortable with this investment, I am excited to see how much more value Durrant and Dale will bring to Humanigen's shareholders.
Thank you for the question.
Something useful??? Like...what you do?
In terms of why I think our pending recall of loaned shares will cause a more significant short squeeze than our first one did, I listed the LIVE-AIR, PREACH-M, RATinG, and the Mayo Clinic-sponsored trial in CAR-T, that could lead to the authorization or approval of lenz. Those were the trials Humanigen highlighted in their last 10-Q. Success in those trials could entice sustained buying interest in Humanigen's stock.
But management also mentioned partnerships and a possible business combination, without going into further detail. I have voiced my opinion that Novavax may be a candidate for a relationship with Humanigen, and noted the covid opportunity for both companies working together.
"Novavax is projecting 30-35M covid vaccinations in the US this 2023-2024 period.
see slide 17
https://www.sec.gov/Archives/edgar/data/1000694/000110465924002100/tm242356d1_ex99-1.htm
If lenz is used as an adjuvant, or is used to enhance Novavax's Matrix-M saponin compound, that would greatly expand the market for lenz as a prophylaxis. But, if lenz is also used in the Combined Influenza Covid (CIC) vaccine, for which they have outlined a faster path forward in bringing to market (slide 14), then that could open a huge new market for lenz."
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173606511
But in addition for lenz to be used as a covid therapeutic, a covid prophylaxis, a CMML preventative, and to enhance bone marrow transplant, and CAR-T enhancement, Novavax mentions the following in regards to their effort to fight malaria.
Malaria "Kills 630,000 people/year, incl ~ 1,300 children/day."
see slide 12 of their presentation linked above.
Is this an additional opportunity for lenz? It seems to me that it is.
"Cytokine-modulating strategies may represent a promising modern approach in disease management. In this review, we discuss the host immune response in malaria, analyzing the latest studies on the roles of pro- and anti-inflammatory cytokines."
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8592744/
I have a long-standing, pro-Novavax bias. But it seems to me that the synergies of these two companies working together hold fantastic potential.
Hi, eb,
Before I forget, I'm sorry I failed to mention covid pneumonia, instead of recent posts where I mentioned just covid. It was not intentional.
Also, thank you for recognizing a degree of plausibility in my assessment of the company's outlook, which is about 180 degrees opposite of Yooo's.
I try to provide the reasons for my opinions by linking the source data. But until the events unfold as I anticipate, I prefer that people have the full spectrum of opinion, and Yooo's posts always provide an opposite view. I find some utility in that.
I don't have access to any private boards, if they are still active. This board is the most active, and Yooo helps to make that true. That's the only affinity I have for him. I expect that there will be a sharp increase in interest from prospective investors in the near term, or at some time, and this board might be useful to them for historical perspective.
Must be true, cause I have no idea what's inspiring your little crusade.
There must be some point to these posts about IR that's gotten you excited. IR seemed to be one of the hats Ed Jordan was wearing until he resigned in September. The company cut staff and contractors, and people are still complaining about salaries being paid. You can't expect business as normal under these circumstances.
Oh my God, four exclamation points! I don't like to use the phone. I don't call anybody.
I emailed IR a few years ago, before the phone call. I got a response from Durrant when I was using their website regarding compassionate use for a friend. I don't have other emails or phone calls from anyone connected to Humanigen, directly or indirectly.
I'm not trying to salt wounds, Yooo. I'm only sincerely trying to assemble the pieces as they are played. I won't be stopping that.
Just because I haven't been proven correct yet...doesn't mean that I have not been right all along. Sorry about the double negative. I know it's hard enough for you to understand already.
Private Messager,
I hadn't noticed the correlation you mentioned. The attempt to flood our message board is intended to distract attention from our progress, so I kind of have Moderna blocked. But when posters here reply to him, I see the post to which they're replying, and I agree with some of his postings regarding the government's unethical role in controlling market access. So I guess it's accurate to say that I have 0.5 persons blocked.
What I did notice though, in your case, was yet another demonstration of the consideration Humanigen has for their shareholders. Whether that was manifested as it was in your case, or by calling me at about 7:30am on the day our EUA was Declined (I sent them a brief note, and the call I got in reply was after the caller had spent the entire night calling foreign investors), or whether that consideration for shareholders is shown by managements' personal involvement in getting the compassionate use of lenz to patient-shareholders, these things demonstrate the character of our management team. I think even their first effort to get a drug to market (it might have been HGEN005) for Chagas Disease, was a compassionate effort to treat a small segment of the world's population, that was totally neglected by Big Pharma.
I hope management achieves all the success they and Humanigen deserve. The world will be a better place, if they do.
Pretty good overview of the ADC market, which I think is relevant to our product pipeline. This sheds some light on 'what's next' for Humanigen.
https://www.marketsandmarkets.com/Market-Reports/antibody-drug-conjugates-market-122857391.html?gad_source=1&gclid=EAIaIQobChMI_-WmxpndgwMV6ROtBh1ysQd4EAAYASAAEgIIIvD_BwE
One thing to note is that Taran entered into an Asset Purchase Agreement with Humanigen, not a Buy Out, to include our pipeline products, the equity in one of our subsidiaries, and "certain causes of action." The main cause of action I want to see is the recall of our loaned shares. Humanigen will do nothing that would eliminate those shares until the short positions have been bought-in. That transaction could leave a substantial amount of cash on the balance sheet, following the resolution of the bankruptcy. It could certainly be enough in value to meet Nasdaq Listing Standards for a number of interested entities.
https://www.sec.gov/ix?doc=/Archives/edgar/data/1293310/000121465924000421/o152468k.htm
Such interested entities could include some of whom we may have engaged, such as Baudax/TeraImmune, Novavax, Gracell, and possibly AstraZeneca.
Our own interest, especially if Taran's purchased subsidiary survives as the Parent company of Humanigen, might best be served in Australia.
"Expansion of the PREACH-M study is a critical next step in our realignment strategy. Associate Professor Thomas is a world expert in CMML and program leader for Blood Cancers at SAHMRI. SAHMRI is a leader in precision medicine that assists patients in finding the proper treatment for their cancer," commented Cameron Durrant, Chairman and CEO of Humanigen. "Lenzilumab was discovered in Australia, so it is only fitting that we leverage the wealth of local knowledge that exists for lenzilumab as we continue clinical development. Expanding the number of sites may accelerate enrollment. We anticipate seeing preliminary results from this study in the first half of 2023."
https://ir.humanigen.com/English/news/news-details/2022/Humanigen-and-SAHMRI-Announce-Expansion-of-the-PREACH-M-Study-of-Lenzilumab-in-CMML/default.aspx
Further, we now know the interim results of the PREACH-M study have been phenomenal.
"Humanigen and the Principal Investigator are assessing regulatory pathways that may enable
early results to support a regulatory submission and potential approval by the Therapeutic Goods Administration in
Australia, which could be expanded through Project Orbis10 to the United States and the United Kingdom."
https://s28.q4cdn.com/539885110/files/doc_news/Humanigen-Presents-Promising-New-Hematologic-Data-from-PREACH-M-Trial-for-Chronic-Myelomonocytic-Leukemia-Treatment-at-the-2023-Europ-OYZCQ.pdf
I think things could come together for us very quickly now, and we could have positive regulatory and structural developments to report, to coincide with, and support, the recall of our loaned shares.
"COVID levels are up to 19 times higher than reported, WHO says as it warns of the potential dangers of repeat reinfection: ‘We don’t know everything about this virus’
Erin Prater
Fri, January 12, 2024...
COVID hospitalizations and ICU admissions rose by 42% and 62%, respectively, in December."
https://www.yahoo.com/finance/news/covid-levels-19-times-higher-155149181.html
What is the covid reinfection rate for lenz-treated patients, I ask for the (100th? 1,000th?) time? Is there a study on-going by a Humanigen partner based on the increased ICU utilization and deaths rates?
No, I don't believe, "...that Cam can pull a short squeeze slaughter over on these funds, again after they were burned once"
I believe Dale and Durrant WILL pull off an even bigger short squeeze than before. In fact, I have no doubt about it.
"Universal coronavirus vaccine may save lives, money in future pandemic
Dennis Thompson, HealthDay News
Fri, January 12, 2024
A universal coronavirus vaccine could have saved millions of lives and billions of dollars if one had been available prior to the pandemic, a new study argues.
Further, a universal vaccine -- one that targets parts of the virus common to all coronaviruses -- could still be a game-changer in the future, researchers say.
But that's only possible if one is developed before another variant mutates and runs rampant through the human population..."
https://www.yahoo.com/news/universal-coronavirus-vaccine-may-save-173805468.html
Lenzilumab.
I should note that Gracell filed a 6-K, also on Jan 8th, which was designated as the Record Date for shareholders who will be able to vote on the merger with AstraZeneca.
I think that much like GSK, AstraZeneca offers significant synergy for Humanigen to consider, if they aren't already.
https://www.astrazeneca.com/partnering/our-areas-of-partnering-interest.html#!
The only other SEC filings I monitor is for Baudax. We know we/Dale bought 500K shares of Baudax at the end of Q2, when they acquired TeraImmune, which I think was our focus of making the purchase.
No, I don't believe that expert traders comprise those holding short positions here. I believe just the opposite, that smart traders are long.
The REAL experts are Dale and Durrant, who provided the loaned shares, and are about to recall those loaned shares.
And by the way, you don't need to be an expert to buy. You just generally can't be a US-domiciled American.
And by the way:
MLK Day, as the holiday is often called, was made a federal holiday in 1983 and was first observed in 1986. The holiday is always celebrated on the third Monday in January, which this year falls on King's actual birthday. Here's what you can expect. U.S. stock exchanges will be closed Monday.
https://www.morningstar.com/news/marketwatch/20240112332/is-the-stock-market-open-on-mlk-day-will-the-post-office-deliver-mail
You will never get it, will you?
Transferring shares between the nominee and the beneficial owner accounts will be reflected as buys and sells. You, and the financial reporting industry, can't take the Form 4's at face value.
Good!! Now explain the design of the share structure and how Humanigen could be holding 92% of the shares they have issued.
I "get" the design of the share structure, which completely obliterates your dull assessment of how management has enriched themselves. How did Humanigen accumulate 110M of the 119M shares they issued?
The failure of the FDA to award our EUA, despite a Hazard Ratio of 2.54, according to the Thorax peer review, is the reason we can't take lenz as the covid standard of care.
Why can't you understand that?
We'll get lenz authorization and approval. How many millions of preventable deaths will be suffered until then is the question.
"These COVID Symptoms Are Red Flags That You Need Medical Attention
Jillian Wilson
Fri, January 12, 2024
Breathing issues, high fever, dizziness and confusion are all reasons to get immediate medical care."
https://www.yahoo.com/news/covid-symptoms-red-flags-medical-104514298.html
I agree that the move to the expert market was by design, and intended to decrease visibility of the on-going corporate actions, in part.
BUT THAT'S FOR OUR BENEFIT.
Our float could very well be 192% of our OS, and management is about to recall our loaned shares. We have become invincible to the market manipulation of our share price. Shorts will have to meet the share price management will demand, which I hope will start at $201. We have never been stronger!!!
How are we represented now, as it relates to the value of our patents?
Durrant intends to keep the share structure intact through the bankruptcy and merger(s).
I recognize that we disagree.
That would be appreciated, Private Messager.
But I'm not surprised about the optics. In fact, I think they support my position, rather than disprove it. There's lots of talk about a concentration of shares at the 100M share level now. How long have I been talking about the company holding 110M of their own shares? The named brokerages with 100M+ shares are likely to become our biggest purchasers, because I think they will have to buy-in their clients' short positions. And how long have I been talking about a merger? How might that relate to what we're seeing about Taran buying the assets of one of our subsidiaries? Is that setting the stage for a parent-subsidiary downstream merger?
I'm just enjoying the show, and trying to learn, as I try to piece together the parts being assembled. I may never have another learning opportunity like this one.
I'm seeing no sign of a course change from the pathway I believe we are taking.
Who said anything about taking the company private? Maybe I missed something, because I'm largely ignoring this whole bankruptcy proceeding. But I do believe that this voluntary CH11 filing makes us much stronger than an involuntary CH7 that could have been filed by creditors.
Those brokers don't appear to be holding proprietary accounts, do they?
Novavax is projecting 30-35M covid vaccinations in the US this 2023-2024 period.
see slide 17
https://www.sec.gov/Archives/edgar/data/1000694/000110465924002100/tm242356d1_ex99-1.htm
If lenz is used as an adjuvant, or is used to enhance Novavax's Matrix-M saponin compound, that would greatly expand the market for lenz as a prophylaxis. But, if lenz is also used in the Combined Influenza Covid (CIC) vaccine, for which they have outlined a faster path forward in bringing to market (slide 14), then that could open a huge new market for lenz.